Navigation Links
ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
Date:8/9/2013

ADDISON, Texas, Aug. 9, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) today announced that it has scheduled a conference call to discuss the second quarter ended June 30, 2013 financial results and to provide a general business update on Thursday, August 15, 2013 at 9:00 a.m. Eastern Time.

To participate in the conference call please dial (800) 357-0498, for international callers dial (850) 429-1388 (access code 24013#) five to ten minutes prior to the initiation of the teleconference.  If you are unable to listen to the live broadcast, a replay of the call will be available starting on August 15, 2013 two hours following the end of the call until August 29, 2013 at 11:59 p.m. Eastern Time.  For the U.S. replay, please dial (866) 415-9493 and international callers please dial (205) 289-3247 (access code 24013#).  You may also access the replay of the call two hours following the end of the call until August 29, 2013 at 11:59 p.m. Eastern Time via the web by logging onto http://app.zelephony.com/multipoint/.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For more information about ULURU Inc., please visit www.uluruinc.com.  For more information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited
'/>"/>

SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ULURU Inc. Reports First Quarter 2013 Financial Results
2. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
3. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
5. ULURU Inc. Business Update And Outlook
6. ULURU Inc. Announces Closing Of $440,000 Private Placement
7. ULURU Inc. Reports Third Quarter 2012 Financial Results
8. ULURU Inc. Announces The First Shipment Of Veterinary Product
9. ULURU Inc. Announces First Order Of Altrazeal For European Launch
10. ULURU Inc. Reports Second Quarter 2012 Financial Results
11. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Orthopedic Instrument Industry Report, 2014-2017" report to their ... and rising proportion of reimbursement for medical expenses, the ... with its scale presenting a CAGR of 19.2% during ... three product segments of orthopedic instruments in ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
... Scientific Corporation (NYSE: BSX ) announces results ... WATCHMAN® Left Atrial Appendage Closure (LAAC) device.  The data ... by 75 percent in patients with atrial fibrillation who ... Vivek Reddy, M.D., Director of Cardiac Arrhythmia Service at ...
... ECTE ), a company developing its needle-free ... glucose monitoring system and its Prelude® SkinPrep System for ... quarter ended March 31, 2012.  Echo,s Quarterly Report on ... through Echo,s website at www.echotx.com . ...
Cached Medicine Technology:Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 2Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 3Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 4Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy 5Echo Therapeutics Announces First Quarter 2012 Financial Results 2Echo Therapeutics Announces First Quarter 2012 Financial Results 3Echo Therapeutics Announces First Quarter 2012 Financial Results 4Echo Therapeutics Announces First Quarter 2012 Financial Results 5
(Date:9/1/2014)... 01, 2014 The National Association of ... that Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, ... American Academy of Nursing. They will be inducted with ... FACHE, whose induction we reported last May. , Our ... during the 2014 American Academy of Nursing Policy Conference ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... San Diego, CA (PRWEB) September 01, 2014 ... website daily regarding all the latest information from the ... , The US FDA announced on August 28, ... are recalled (Class I) as the device ... FDA, the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 ... into Heartbeat Experts’ perspectives on stakeholder ... , Download the flash report to speak ... any launching Diabetes product:, , ... an increasingly crowded market ,     Understanding ...
(Date:8/31/2014)... 31, 2014 Just in time for Washington’s ... only wild, sustainable Alaska Salmon, award winning chowder ... Duke's Green Lake location , Sunday, September 28, 2014 ... sample several ethnic salmon BBQ culinary delights. Live music will ... from Hawaii, Puerto Rico and Mexico will be featured. ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... ... and Insurance Services, a leading provider of information-based technology services to the ... in Louisiana and Texas in addition to its services that are provided ... headquartered in Hampton, New Hampshire and is owned by Medical Protective, part ...
... , , ARLINGTON, Va., ... that a panel of independent scientific experts convened by the ... a reproductive or developmental toxicant. After a thorough review ... Committee determined that bisphenol A should not be listed under ...
... WASHINGTON, July 15 On behalf of the nation,s mayors, ... commended President Barack Obama, the House of Representatives and the Senate ... transformative health care reform legislation. , ... times because they are not able to afford health insurance and, ...
... , SCOTTSDALE, Ariz., July 15 Grubb ... of America, Inc.) (the "REIT"), a self-managed non-traded real estate ... agreement (the "Agreement") to acquire a 16 building portfolio from ... transaction involves approximately 855,000 square feet of medical office and ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... , , , ... presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory ... and docetaxel did not provide a sufficient benefit-risk ... cancer. , , Women with locally advanced ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:California Expert Panel Concludes Bisphenol A is Not a Reproductive or Developmental Toxicant 2Health News:The Nation's Mayors Commend New Healthcare Reform Legislation 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: